Skip to main content
OpenTrials
Completed

NCT Number: NCT00426010

Measuring Placebo Effect by Elimination and Investigating Mechanism of Action

We propose to measure the effect of placebo by elimination as well as by a "balanced placebo" design, determine its interaction with active drug, and explore whether placebo exerts part of its effect at the pharmacokinetics level.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Clinical Studies & Empirical Ethics, KFSH & RC

Riyadh, 11211, Saudi Arabia

About this study

Placebos have been in use for centuries in medical practice. However, there is continued controversy regarding their effectiveness and mechanisms of action.

The results of the study are expected to further our understanding of a widely used medical intervention, i.e., placebo, and of how to maximize its potential beneficial effect. It will also help assess the appropriateness of measuring the placebo effect by elimination, which has important ethical implications in relation to the design of randomized clinical trials.

Comparison: caffeine vs placebo. Dependent variables:4 hours area under the curve (AUC) of pharmacodynamics endpoints as well as pharmacokinetics endpoints in a subgroup.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and nonpregnant females 18 and 40 years of age with at least high school education.

Exclusion criteria

  • Include evidence of clinically relevant deviation from normal health (such that it may affect the endpoints, make the ingestion of caffeine dangerous, or affect the pharmacokinetics/pharmacodynamics of caffeine),
  • Pregnancy,
  • Poor venous access,
  • Hypertension (more than 140/90),
  • Heart disease,
  • History of panic attacks,
  • Average daily caffeine consumption of more than 300 or less than 100 mg,
  • Smoking,
  • Alcohol abuse,
  • Taking any medication other than birth control bills (including over-the-counter drugs) within one week from starting the study,
  • Hypersensitivity to caffeine or related compounds,
  • Hemoglobin of less than 13 gm/L, and recent (one week) acute illness

Treatment and study plan

caffeine/placebo

Drug

caffeine or placebo, either overt or covert

Primary outcomes

  1. 4 hours area under the curve (AUC) of peripheral systolic blood pressure

    Time frame: 4 hours

  2. 4 hours area under the curve (AUC) of energy level measured by Visual Analogue Scales.

    Time frame: 4 hours

  3. 4 hours area under the curve (AUC) of alertness level measured by Visual Analogue Scales.

    Time frame: 4 hours

  4. 4 hours area under the curve (AUC) of nausea measured by Visual Analogue Scales.

    Time frame: 4 hours

Secondary outcomes

  1. Cmax of serum caffeine (in a subgroup)

    Time frame: 4 hours

  2. Tmax of serum caffeine (in a subgroup)

    Time frame: 4 hours

  3. t1/2 of serum caffeine (in a subgroup)

    Time frame: 14 hours

  4. AUC of serum caffeine (in a subgroup)

    Time frame: 14 hours

Sponsors and collaborators

Lead sponsor

King Faisal Specialist Hospital & Research Center

Other

Collaborators

  • King AbdulAziz City for Science and Technology

Registry information

Official study title

Measuring Placebo Effect by Elimination and Investigating Its Mechanism of Action

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Jan 24, 2007
Registry last updated
Dec 13, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.